This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PF (pulmonary fibrosis)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pulmonary fibrosis is a condition in which there is diffuse fibrosis of lung parenchyma with a resultant impairment of gas transfer and ventilation-perfusion mismatching.

Fibrosis within the lung may be:

  • replacement fibrosis, secondary to disorders such as:
    • infarction
    • pneumonia
    • tuberculosis

  • focal fibrosis, in response to irritants such as:
    • silica
    • coal dust

  • interstitial fibrosis:
    • cryptogenic (idiopathic) fibrosing alveolitis
    • extrinsic allergic alveolitis

Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure (1):

  • most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective tissue disease (CTD), accounting for 25% of ILD cases
  • typically presents with dyspnea on exertion
  • approximately 30% of patients with ILD report cough

Reference:

  1. Maher TM. Interstitial Lung Disease: A Review. JAMA. Published online April 22, 2024. doi:10.1001/jama.2024.3669

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.